IL17A and psoriasis vulgaris: With extensive research and a deeper understanding of the pathogenesis of psoriasis in the past 20 years, biological therapies targeting TNF, IL-23/IL17, JAK1/JAK3, and PDE4 showed excellent efficacy and fewer side effects, which have been approved by FDA to treat moderate-to-severe plaque psoriasis.